MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ -- MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose's proprietary electronic inhaler technology and Vectura's dry powder insulin formulation. The QDose inhaled insulin product offers dose titration capability over a broad range of dose strengths, in a single inhalation. The inhaler also provides active dose feedbacks to the patient in an easy to use, pocket-sized device.
